Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Purchased by Alberta Investment Management Corp

Alberta Investment Management Corp raised its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 44.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,600 shares of the company’s stock after acquiring an additional 11,800 shares during the quarter. Alberta Investment Management Corp owned approximately 0.07% of Harmony Biosciences worth $1,328,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Pacer Advisors Inc. grew its holdings in shares of Harmony Biosciences by 18.2% in the fourth quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company’s stock valued at $78,452,000 after purchasing an additional 351,582 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in Harmony Biosciences by 27.1% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company’s stock valued at $26,416,000 after buying an additional 140,690 shares during the period. HealthInvest Partners AB grew its stake in shares of Harmony Biosciences by 335.2% in the third quarter. HealthInvest Partners AB now owns 151,875 shares of the company’s stock worth $6,075,000 after acquiring an additional 116,975 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Harmony Biosciences by 68.4% during the third quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company’s stock worth $9,217,000 after acquiring an additional 93,622 shares during the period. Finally, HighTower Advisors LLC raised its stake in shares of Harmony Biosciences by 364.0% in the third quarter. HighTower Advisors LLC now owns 79,961 shares of the company’s stock valued at $3,199,000 after acquiring an additional 62,729 shares in the last quarter. 86.23% of the stock is currently owned by hedge funds and other institutional investors.

Harmony Biosciences Stock Down 0.9 %

Shares of NASDAQ:HRMY opened at $34.56 on Friday. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The firm has a 50 day simple moving average of $36.53 and a 200-day simple moving average of $35.74. The company has a market capitalization of $1.97 billion, a PE ratio of 16.38, a P/E/G ratio of 0.47 and a beta of 0.80. Harmony Biosciences Holdings, Inc. has a twelve month low of $28.14 and a twelve month high of $41.61.

Analysts Set New Price Targets

Several research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and set a $75.00 target price on shares of Harmony Biosciences in a research note on Wednesday. Mizuho lowered their price objective on Harmony Biosciences from $52.00 to $42.00 and set an “outperform” rating for the company in a research report on Thursday. Cantor Fitzgerald raised their target price on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. Oppenheimer reiterated an “outperform” rating and set a $59.00 price target (up previously from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Finally, Needham & Company LLC reduced their price objective on shares of Harmony Biosciences from $52.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Harmony Biosciences currently has a consensus rating of “Buy” and a consensus target price of $53.67.

Insider Activity at Harmony Biosciences

In other news, insider Jeffrey Dierks sold 1,123 shares of Harmony Biosciences stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $40.00, for a total transaction of $44,920.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Sandip Kapadia sold 25,000 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $40.18, for a total value of $1,004,500.00. The disclosure for this sale can be found here. Insiders sold a total of 72,452 shares of company stock valued at $2,831,679 over the last ninety days. Insiders own 30.80% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.